Rhythm Pharmaceuticals (RYTM) EBT Margin (2021 - 2026)
Rhythm Pharmaceuticals (RYTM) posted quarterly EBT Margin of 91.65% for Q1 2026, up 5945.0% year-over-year from 1.52% in Q1 2025, and down 10.39% quarter-over-quarter from 83.03% in Q4 2025.
Rhythm Pharmaceuticals (RYTM) EBT Margin (2021 - 2026) Analysis & Trends
Rhythm Pharmaceuticals (RYTM) has reported EBT Margin for 6 consecutive years, with 91.65% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT Margin rose 5945.0% year-over-year to 91.65%; the TTM figure through Mar 2026 stood at 92.89% (up 3028.0% YoY), while the FY2025 annual figure was 103.31%, up 9669.0% from the prior year.
- EBT Margin eased to 91.65% in Q1 2026 per RYTM's latest filing, from 83.03% in the prior quarter.
- Across five years, EBT Margin topped out at 527.99% in Q4 2022 and bottomed at 3693.79% in Q1 2022.
- Historically, EBT Margin has averaged 418.76% across 5 years, with a median of 151.11% in 2025.
- On a YoY basis, EBT Margin climbed as much as 1422548 bps in 2022 and fell as far as 19156808 bps in 2022.
- Rhythm Pharmaceuticals' EBT Margin stood at 527.99% in 2022, then slumped by 132 bps to 170.99% in 2023, then soared by 39 bps to 103.71% in 2024, then climbed by 20 bps to 83.03% in 2025, then fell by 10 bps to 91.65% in 2026.
- Business Quant data shows RYTM's EBT Margin at 91.65% in Q1 2026, 83.03% in Q4 2025, and 102.91% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 34.77% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 18.33% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -94.22% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.77% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -2.67% |
| 10 | Rhythm Pharmaceuticals | 7.95 Bn | 7.62 Bn | 62.32 Mn | -68.56% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -68.56% |
| Mar 31, 2026 | -91.65% |
| Dec 31, 2025 | -83.03% |
| Sep 30, 2025 | -102.91% |
| Jun 30, 2025 | -95.45% |
| Mar 31, 2025 | -151.11% |
| Dec 31, 2024 | -103.71% |
| Sep 30, 2024 | -132.28% |
| Jun 30, 2024 | -109.30% |
| Mar 31, 2024 | -543.27% |
| Dec 31, 2023 | -170.99% |
| Sep 30, 2023 | -194.61% |
| Jun 30, 2023 | -242.98% |
| Mar 31, 2023 | -454.96% |
| Dec 31, 2022 | 527.99% |
| Sep 30, 2022 | -953.80% |
| Jun 30, 2022 | -523.06% |
| Mar 31, 2022 | -3,693.79% |
| Dec 31, 2021 | -2,975.73% |
| Sep 30, 2021 | -4,602.14% |